• Extensive stage SCLC (Es-SCLC)
• Extensive stage SCLC (Es-SCLC) - maintenance (M) 2
• Extensive stage SCLC (Es-SCLC) - 1st Line (L1) 5
• Extensive stage SCLC (Es-SCLC) - 2nd line (L2)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab plus SoC
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC
• durvalumab based treatment
• durvalumab plus etoposide and platin
• pembrolizumab based treatment
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• durvalumab plus tremelimumab plus SoC

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs etoposide plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC

  All patients Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PDL1 (CPS < 1) PDL1 (CPS >1) smoker (Current) smoker (Former)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

Extensive stage SCLC (Es-SCLC) - 1st Line (L1), pembrolizumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;